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Abstract
The C-terminal region of the M-protein of Streptococcus pyogenes is a major target for vac-
cine development. The major feature is the C-repeat region, consisting of 35–42 amino acid
repeat units that display high but not perfect identity. SV1 is a S. pyogenes vaccine candidate
that incorporates five 14mer amino acid sequences (called J14i variants) from differing C-
repeat units in a single recombinant construct. Here we show that the J14i variants chosen
for inclusion in SV1 are the most common variants in a dataset of 176 unique M-proteins.
Murine antibodies raised against SV1 were shown to bind to each of the J14i variants present
in SV1, as well as variants not present in the vaccine. Antibodies raised to the individual J14i
variants were also shown to bind to multiple but different combinations of J14i variants, sup-
porting the underlying rationale for the design of SV1. A Lewis Rat Model of valvulitis was
then used to assess the capacity of SV1 to induce deleterious immune response associated
with rheumatic heart disease. In this model, both SV1 and the M5 positive control protein
were immunogenic. Neither of these antibodies were cross-reactive with cardiac myosin or
collagen. Splenic T cells from SV1/CFA and SV1/alum immunized rats did not proliferate in
response to cardiac myosin or collagen. Subsequent histological examination of heart tissue
showed that 4 of 5 mice from the M5/CFA group had valvulitis and inflammatory cell infiltra-
tion into valvular tissue, whereas mice immunised with SV1/CFA, SV1/alum showed no sign
of valvulitis. These results suggest that SV1 is a safe vaccine candidate that will elicit anti-
bodies that recognise the vast majority of circulating GASM-types.
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Introduction
Streptococcus pyogenes (group A streptococcus, GAS) is Gram-positive bacterium responsible
for a wide range of diseases in humans. These include self-limiting pharyngitis, skin infections,
invasive diseases and the autoimmune sequelae post-streptococcal glomerulonephritis, rheu-
matic fever (RF) and Rheumatic Heart Disease (RHD). The majority of these cases occur in
developing nations and Indigenous communities within developed nations, where both strep-
tococcal carriage and infection are considered to be endemic [1–4]. It has been estimated that
up to half a million people die of GAS related diseases each year [5]; hundreds of millions more
suffer from the less severe diseases.
This burden of GAS disease positions the causative organism as one of the major human
pathogens for which no vaccine is available. The M-protein, a major virulence determinant
found on the surface of GAS, is the favored target of most vaccine development programs [6].
The major role of the M-protein is inhibition of phagocytosis through prevention of deposition
of complement on the bacterial surface. The M-protein also has a secondary role as an adhesin,
and has been shown to bind multiple extracellular matrix proteins [7]. Structurally the protein
extends as a coiled coil dimer from the cell wall to beyond the peptidoglycan layer (Fig 1). The
secondary structure of the M-protein is maintained by a repeating heptad motif that includes
hydrophobic moieties at the first and fourth amino acid residues, and helix promoting amino
acids at other sites [8, 9]. The amino-terminus of the M-protein is considered to be hypervari-
able, and used to define the more than 200 different GAS emm-types [10]. Natural and vac-
cine-induced antibodies to this region are bactericidal, but typically only confer emm-type
specific protection [11–13]. The presence of epitopes in the B-repeat region of the protein asso-
ciated with autoimmune sequelae [14] preclude its use in any vaccine candidate.
The highly conserved C-Repeat Region (CRR), found in the C-terminal half of the M-protein
has been the target of several vaccine programs [15–19]. The CRR of most M-proteins contains 3
repeat units that are similar, but not identical [20, 21]. The variant sequences present in individual
C-repeat units (CRU) are named on the basis of differences in an internal amino acid sequence
that corresponding to the J8i peptide or overlapping J14i peptide sequences [21, 22]. The J14i vari-
ant sequences found in these repeat units are generally conserved within an emm-type, but vary
between emm-types. Currently 76 different J14i types have been described. When flanked by
amino acid sequence required for maintenance of alpha-helical structure, and linked to carrier
molecule such as diphtheria toxoid, the prototype J8i and J14i peptide sequences have been shown
to induce antibody responses that are bactericidal and protect mice from GAS challenge [16, 17].
Our approach to GAS vaccine development has been to identify common J14i variant
sequences present in different C-repeat units (CRUs) and link them into a single recombinant
construct (Fig 1) [19]. SV1 contains five such sequences (J14i.0, J14i.1, J14i.2, J14i.4, J14i.29).
Each one of the J14i variant peptides present in SV1 consists of 14 amino acids. Consequently,
SV1 maintains an alpha-helical structure without the need for additional flanking sequence
and SV1 is also immunogenic in mice. Anti-SV1 antibodies also bind to the surface of three
GAS emm-types (emm1, emm97 and emm65), and are bactericidal towards the two GAS emm-
type (emm97 and emm65) strains tested. The aim of the current study is to assess the emm-
coverage afforded by SV1 and the immuno-safety of this vaccine. We report that the five J14i
variants represented in SV1 are present in 97% of M-proteins [23]. Furthermore, SV1 antibod-
ies recognize J14i variants not present in the vaccine construct, potentially extending vaccine
coverage to emm-types that lack representation in the SV1 vaccine construct. Finally we also
demonstrate that SV1 immunization does not induce cross-reactive immune responses as
determined using a Lewis Rat model of valvulitis. Together these results suggest that SV1 has
significant potential as a safe and universal GAS vaccine candidate.
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Materials and Methods
Bacteria, proteins and peptides
The GAS strains used in this study (Table 1) have all previously been described [20, 24, 25].
They represent 9 different emm-types, and one emm-negative strain. The strains also represent
each of the major clusters proposed as part of the new emm-types clustering system [20]. All
isolates were grown in sterile Todd Hewitt Broth supplemented with 1% neopeptone or on
Columbia Blood agar containing 5% sterile horse blood. Recombinant proteins were expressed
Fig 1. (A) Schematic diagram of the M-protein. The hypervariable region, B and C-repeat regions (CRR)
and C-repeat units (CRUs) are depicted. The location of J14i variant peptide sequences within each of the
CRUs are shown as black boxes. The figure is not drawn to scale. (B) Schematic of SV1. The location and
identity of each J14i sequence is shown.
doi:10.1371/journal.pone.0156639.g001
Table 1. GAS strains used in the study.
Strain emm-type emm-cluster CRU1 CRU2 CRU3
JRS145 emm-negative
PRS8 emm12 A-C4 J14i.16 J14i.2 J14i.0
PRS9 emm19 M19 J14i.4 J14i.2 J14i.0
PRS15 emm48 E6 J14i.36 J14i.1 J14i.1
PRS20 emm60 E1 J14i.12 J14i.1 J14i.1
PRS30 emm83 D4 J14i.2 J14i.2 J14i.0
PRS42 emm99 E6 J14i.36 J14i.1 J14i.1
PRS55 emm9 E3 J14i.29 J14i.1 J14i.1
PL1 emm54 D1 J14i.4 J14i.2 J14i.0
5448 emm1 A-C3 J14i.2 J14i.2 J14i.0
5448 AP emm1 A-C3 J14i.2 J14i.2 J14i.0
5448Δ hasA emm1 A-C3 J14i.2 J14i.2 J14i.0
doi:10.1371/journal.pone.0156639.t001
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in Escherichia coli and purified using nickel affinity chromatography. Peptides were synthe-
sized to 95% purity by Mimotopes (Table 2).
Murine immunization
Female six-week old BALB/c mice (Animal Resources Centre, Perth, Australia) were subcuta-
neously immunized with 25μg of antigen admixed in a 1:1 ratio with alum delivered in a final
50μ volume. Secondary, tertiary and quaternary boosts consisting of 10μg protein emulsified
1:1 with aluminium hydroxide were delivered on days 21 and 28 and 35. Blood was collected
prior to each immunization and 7 days after the final immunization. Sera from the final bleed
was used in all assays reported here. All murine work was approved by the QIMR Berghofer
Animal Ethics Research Committee (A0311-641).
Secondary structure
The secondary structure of 14mer peptides in solution was investigated by circular dichromic
spectra acquired with a JASCO J-715 CD Spectropolarimeter at 20°C. Peptide solutions were
assessed at 0.02 mg/mL in 10 mM sodium phosphate, 20 mM NaCl, pH 8.0. Far UV-CD spec-
tra were acquired at from 260 to 190 nm in 0–50% 2,2-trifluoroethanol (TFE). All spectra were
corrected for buffer baseline and converted to mean residue ellipticity (θ) using the software
ACDP v2.9 [26] and compared with the software SDAR v2.9 [27]. The amount of TFE required
to observe alpha-helical secondary structure is based on the appearance of a peak at 208 nm.
For each peptide, secondary structure was predicted based on its amino acid sequence using
the software PSIPRED [28].
Table 2. Peptides used in the study.
Peptide Sequence %TFE required for helical structure
J14.0i ASREAKKQVEKALE
a 40
J14.1i ASREAKKKVEADLA 40
J14.2i ASREAKKQVEKDLA 40
J14.4i ASREAKKQLEAEHQ 20
J14.29i ASRAAKKDLEAEHQ >50
J14.8i ASRAAKKELEAEHQ >50
J14.12i ASRAAKKELEAKHQ 40
J14.36i ASRAAKKELEANHQ 40
J14.53i GSRAAKKELEAKHQ 20
J14.57i ASRAAKKELEAKHQ 40
J14.0i KQAEDKVKASREAKKQVEKALEQLEDKVK
J14.1i KQAEDKVKASREAKKKVEADLAQLEDKVK
J14.2i KQAEDKVKASREAKKQVEKDLAQLEDKVK
J14.4i KQAEDKVKASREAKKQLEAEHQQLEDKVK
J14.29i KQAEDKVKASRAAKKDLEAEHQQLEDKVK
J14.8i KQAEDKVKASRAAKKELEAEHQQLEDKVK
J14.12i KQAEDKVKASRAAKKELEAKHQQLEDKVK
J14.36i KQAEDKVKASRAAKKELEANHQQLEDKVK
J14.53i KQAEDKVKGSRAAKKELEAKHQQLEDKVK
J14.57i KQAEDKVKASRAAKKELEAKHQAQLEDKVK
a The underlined section of each 14mer peptide indicates predicted α-helical structure, as determined by PSIPRED.
doi:10.1371/journal.pone.0156639.t002
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ELISA
The wells of PVC micro-titer plates were coated with 100μl of a solution containing 500ng/ml
peptide or protein diluted in 0.05M sodium carbonate coating buffer (pH 9.6). After incuba-
tion, the wells were blocked with 5% skim milk in PBS containing 0.05% Tween20 (PBS-T) and
incubated at 37°C for 90 minutes, or overnight at 4°C. Two fold serial dilutions of sera were
made and incubated at 37°C for 90 minutes. The sera were decanted and plate washed with
PBS-T prior to addition of HRP conjugated goat anti-mouse secondary antibody (AbD Sero-
tec) diluted 1:3000 in 0.5% skim milk/PBS-T. After incubating at 37°C for 90 minutes the plates
were washed, o-Phenylenediamine Dihydrochloride was added to the wells, and incubated
again at room temperature. The absorbance (450nm) was then measured. Antibody titers were
defined as the reciprocal of the highest dilution of samples that yielded an optical density at
450nm of more than 3 standard deviations above the mean optical density of pre-immune sera.
Statistically significant differences in ELISA titers were assessed using ANOVA and Kruskal
Wallace non-parametric tests.
Immunofluorescent Microscopy
Immunofluorescent microscopy was carried out essentially as previously described [29].
Briefly, bacteria were grown overnight, washed, and fixed to a polylysine coated slide (ProSci-
Tech) with 3% paraformaldehyde. The fixed slides were then blocked with 5% skim milk/
PBS-T. To prevent non-specific Fc-IgG binding by streptococcal surface proteins the slides
were exposed to a second blocking step using non-specific human polyclonal IgG (AbD Sero-
tec) was undertaken. The slides then were incubated with pooled murine antisera (1:200),
washed, and incubated with secondary goat anti-mouse-IgG-FITC labelled antibody (Invitro-
gen, USA) diluted 1:200 in 0.5% skim milk/PBS-T. The slides were mounted in Prolong Gold
(Life Technologies) and viewed with a 100x objective lens using a 473nm laser with absorbance
of 500-650nm on an Olympus Fluoview FV1200 Confocal Laser Scanning microscope.
Western Blotting
Purified recombinant M-protein, porcine cardiac myosin (Sigma-Aldrich) and skeletal muscle
tropomyosin (Sigma-Aldrich) were electrophoresed on 12% or 4–15% gradient SDS-PAGE
gels, transferred to Hybond C nitrocellulose membranes (Amersham, USA), and blocked with
5% skim milk/PBS-T. The membranes were then incubated with murine anti-SV1 sera diluted
1:2000 in 5% skim milk/PBS-T, washed, and secondary goat anti-mouse IgG-HRP diluted
1:10,000 in PBS-T added. Following 60 min incubation, the membrane was washed, covered
with chemiluminescent substrate (ECLWestern Blotting Detection Reagent, Amersham) fol-
lowing manufactures instructions and exposed to standard X-ray film.
Immonosafety of SV1
The immuno-safety of SV1 was evaluated in a Lewis rat model of autoimmune valvulitis [30,
31]. Lewis rats (LEW/sSN; Albino: a,h,c: RT1) were purchased from the Animal Resources
Centre (Canning Vale, Western Australia) and bred by sibling mating in Small Animal Breed-
ing Facility at James Cook University (Townsville, Australia). For all immunisations rats were
initially anaesthetised using 5% Isoflurane (Provet, Queensland, Australia) and 1–2 L/min O2.
The Isoflurane level were subsequently maintained at 2% during immunization procedures.
Following immunisation a local anaesthetic cream containing 25mg/g lignocaine and 25 mg/g
prilocaine was applied to the injection site. Eight to twelve week-old female Lewis rats were
subcutaneously immunized on day 0 in the hock of the hind left foot with 0.5 mg of SV1 or
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recombinant M5-protein emulsified with Complete Freund's Adjuvant (CFA), or intramuscu-
larly with the same proteins admixed in 2% alum. Negative control rats were immunized with
PBS in adjuvant. On days 1 and 3, the rats were intraperitoneally injected with 0.3μg Bordetella
pertussis toxin (Sigma, Australia). Antigen boosts consisting of 0.5 mg of protein emulsified 1:1
with incomplete Freund's adjuvant, or admixed 2% alum were subcutaneously delivered on
day 7. All animals were euthanased on day 21 by CO2 asphyxiation in a lethal chamber, fol-
lowed by cervical dislocation. Blood, hearts and spleens were then collected.
To determine sera immunoglobulin G (IgG) reactivity, 10 μg/ml of M5, SV1, porcine car-
diac myosin of collagen-1 (Sigma-Aldrich, St. Louis, MO) were coated onto Nunc Maxisorp
plates (Roskilde, Denmark) overnight and test sera added with controls. A secondary goat anti-
rat IgG (Abd Serotec) was used before OD was measured at 405nm in an ELISA plate reader.
Mononuclear cells were aseptically isolated from spleens and T cell proliferation assays per-
formed. Mononuclear cells from each group of rats were cultured in triplicate at 105 cells/well
in RPMI-1640 culture medium with supplement. Cells were stimulated by the addition of
10 μg/ml SV1, M5, porcine cardiac myosin or collagen type 1 or 5 μg/ml concanavalin A
(ConA). The cells were pulsed with 0.25 μCi 3H-thymidine (GEHealthcare, Australia), har-
vested onto filter mats, and counts per minute (CPM) determined using a Microlux beta scin-
tillation counter [25, 26]. Proliferative responses are reported as the change in CPM between
stimulated and unstimulated cells. Histological studies on cardiac tissue were carried out on rat
hearts fixed in neutral buffered formalin and embedded in paraffin. Sections were stained with
hematoxylin and eosin (H&E) and examined under a light microscope for evidence of valvuli-
tis. All experiments using the rat model of valvulitis were approved by the James Cook Univer-
sity Ethics Committee (A1688).
FACS analysis
FACS was used to assess the binding of anti-sera to the surface of three GAS isolates that dif-
fered in their capsule expression levels [19]. GAS 5448 is an emm1 clinical isolate associated
with invasive disease outbreaks [32]. GAS 5448AP is a hypervirulent derivative of GAS 5448
that, due a CovRS mutation, overexpresses capsule [33, 34]. GAS ΔhasA possesses a mutation
in the capsular encoding hasA genes, resulting in abrogation of capsule expression. Bacteria
were grown to mid log-phase, washed in PBS, and then incubated with human IgG in 0.3%
BSA/PBS/Tween to block non-specific binding. The cells were sequentially incubated with pri-
mary antibody, followed by secondary goat anti-mouse FITC conjugated IgG, washed and
fixed in 4% paraformaldehyde. Fluorescence was measured using a FACSort flow cytometer,
and mean fluorescence intensity (MFI) determined. Statistical significant differences in MFI
between PBS and experimental groups was subsequently assessed using by t-test.
Results
J14i-variants present in SV1 are common in 97% of 173 emm-types
The selection of the J14i variants present in SV1 was originally made after the examination of
genes representing 77 different emm-types that were present in the Genbank database [19]. A
subsequent study of emm-gene sequences of greater than 1000 globally distributed GAS iso-
lates provided the opportunity to expand the analysis of the coverage of J14i variants repre-
sented in SV1 to a larger dataset that include 173 unique emm-genes [23]. As the earlier study
showed that the C-terminal amino acid sequences to be highly conserved within an emm-type,
and to avoid bias due to over-representation, individual representatives of each emm-type were
selected for the current analysis. Of the 173 unique emm-genes, all but five (emm134,
emm174, emm137, emm205 and emm211) contained at least one of the J14i variants represent
Predicted Coverage of a Novel Group A Streptococcal Vaccine
PLOS ONE | DOI:10.1371/journal.pone.0156639 June 16, 2016 6 / 17
in SV1 (S1 Table). Sixty (35%) of these putative M-proteins possessed one variant, 90 (52%)
possessed two variants, and 18 (10%) possessed three of these variants. J14i.0 and J14i.1 were
the two most common variants, present in 43% and 51% of emm-types respectively. J14i.2,
J14i.4 and J14i.29 were present in 41%, 21% and 12% of the emm-types respectively. These lat-
ter three variants were the most prevalent J14i variants in CRU1, the CRU most distant from
the bacterial surface (Table 3). J14i.0 was only found in the CRU1. Finally, 512 individual
CRUs were present within the 173 M-proteins analyzed. Of these, 422 possessed a J14i variant
present in SV1. Together these results demonstrate that J14i sequences present in SV1 are pres-
ent in 97% of the emm-types examined in this study, and account for the majority of all J14i
sequences.
SV1 antibodies recognize multiple J14i variants
To show that anti-SV1 antibodies did actually recognise and bind to the individual J14i variants
represented in the vaccine, sera collected after final immunisation of mice was used in ELISA
against a panel of J14i variant peptide sequences (Fig 2). The panel included the variants
Table 3. Distribution of J14i variants in CRUs.
% distribution of J14i-variants
CRR1 CRR2 CRR3 All
J14i.0 0.0 0.0 45.47 44.6
J14i.1 4.6 44.8 49.1 50.8
J14i.2 26.3 36.6 0.6 41.7
J14i.4 20.4 8.7 0.0 21.1
J14.29i 13.2 1.16 0.0 12.0
doi:10.1371/journal.pone.0156639.t003
Fig 2. Peptide specific serum IgG responses of mice immunized with SV1. Data is presented as the
mean ± standard deviation of ten mice per group. Anti-SV1 titers were significantly greater than anti-PBS
titers for all peptides (p < 0.05). Black bars represent mean titers observed using anti-SV1 antisera. Open
bars represent mean titres observed using anti-PBS antisera.
doi:10.1371/journal.pone.0156639.g002
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present in SV1 and five additional J14i sequences. These latter peptides were included to assess
the capacity of SV1 antibodies to bind other J14i sequences and were selected for inclusion on
the basis of their ubiquity (J14i.8, J14i.12, J14i.8, J14i.36) or because they possessed unique
sequences at specific amino acid sites (J14i.53 and J14i.57). The mean titers for the five SV1 rep-
resented variants ranged from 3.3x105 ± 9.6 x104 to 8.7 x104 ± 2.5 x104. For the peptides not
present in SV1, the highest titers were observed using J14i.8 (3.1x10
5 ± 2.5 x104) and anti-
J14i.57 (2.1x10
5 ± 2.5 x104). There were no significant differences between the mean titers
observed for these two peptides, and those observed with any of the peptides presents in SV1 as
determined using by ANOVA and Kruskal Wallace non-parametric test. Titers against the
remaining three other peptides (J14i.12, J14i.36 J14i.53) were lower, but still significantly higher
than titers observed for PBS sera negative control sera. Together these results demonstrate
anti-SV1 antibodies are capable of recognizing multiple J14i variants, increasing targets for
SV1 antibodies on the bacterial surface, and potentially increasing the emm-type coverage
afforded by SV1.
To determine which variants present of SV1 contribute to cross-recognition, antisera were
raised against J14i peptides. As individual J14i peptides are poorly immunogenic, the J14i pep-
tides were resynthesized with GCN4 flanking amino acid sequences, designed to maintain the
alpha-helical conformation of the parental M-protein, and conjugated to diphtheria toxoid
prior to immunization of mice. Sera from individual mice in each group were then pooled and
used in ELISAs against the panel of 10 J14i variant peptides. For these assays, a titer of 1000
was chosen as an arbitrary cut-off value representing low or no binding between sera and pep-
tide (Table 4). As expected, antibody titers for individual sera were highest when used against
the corresponding J14i peptide sequence as capture antigen. Anti-J14i.0 anti-sera also bound to
J14i.1, J14i.2, J14i.29 and J14i.57. Titers for anti-J14i.1 anti-sera were greater than 1000 against
an additional two peptide sequences. Sera raised to J14i.2 and J14i.4 recognised 4 and 6 peptides
respectively. Despite showing low titers against J14i.29, anti-J14i.29 anti-sera also bound to two
peptides. Collectively, nine of the ten peptides examined were recognized by at least one of
these peptide antisera. The differences in peptides recognized by the different anti-sera under-
score the utility of incorporating multiple J14i variants in a single construct.
To identify factors that may contribute to the cross-recognition, the percentage identity
between J14i peptides was determined (Table 5), and compared to the corresponding ELISA
titer (Fig 3). This analysis has shown that for sera tested, there was a correlation between titer
and relative identity between peptides. Using a titer of 1000 as the cut-off point as described
above, cross-recognition was observed in 15 of 23 cases where the identity between J14i pairs
was greater than 70%, but only one instance amongst 23 pairs where the identity between
sequences was less than 70%.
Table 4. Relative cross-recognition between peptide specific antisera and J14i-variant peptides.
Peptide
J14i.0 J14i.1 J14i.2 J14i.4 J14i.29 J14i.8 J14i.12 J14i.36 J14i.53 J14i.57
Anti-sera J14.0 +++a + ++ - + - - - - ++
J14.1 ++ +++ - - - - - - - +
J14.2 + ++ ++ - - - - - - ++
J14.4 - + - +++ + + ++ - + -
J14.29 - - - + + + - - - -
a Titers less than 1000 (-); titers between 1000–10,000 (+); titers between 10,000–100,000 ‘++’; titers greater than 100,000 ‘+++’
doi:10.1371/journal.pone.0156639.t004
Predicted Coverage of a Novel Group A Streptococcal Vaccine
PLOS ONE | DOI:10.1371/journal.pone.0156639 June 16, 2016 8 / 17
Anti-SV1 antibodies recognize multiple M-proteins
The data above demonstrate that the design strategy for SV1 has resulted in a recombinant
construct that is immunogenic and evokes antibody responses in the presence of a human
Table 5. Percent identity between J14i peptides.
J14i.0 J14i.1 J14i.2 J14i.4 J14i.29 J14i.8 J14i.12 J14i.36 J14i.53 J14i.57
J14.0i 100 71 86 64 57 50 50 50 43 86
J14.1i 100 86 71 57 57 57 57 50 79
J14.2i 100 64 50 50 50 50 43 93
J14.4i 100 86 86 79 79 71 64
J14.29i 100 93 86 79 79 50
doi:10.1371/journal.pone.0156639.t005
Fig 3. Correlation between antibody titer and peptide identity. The ELISA titer for each J14i peptide
antisera/peptide combination is plotted against the percent identity of the two corresponding peptides.
Percent identity is plotted on the x-axis. Corresponding titers are plotted on the y-axis. Linear regression
revealed that a significant correlation between these two variables exists for each antisera. The dotted
horizontal line shows the cut-off used as the titre used to differentiate between low or non-significant binding,
and significant binding.
doi:10.1371/journal.pone.0156639.g003
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approved adjuvant that theoretically should be capable of binding to the CRR of multiple M-
proteins. To confirm this we subsequently conducted Western blots against eight M-proteins
representing different emm-types and emm-type clusters. Binding was observed in all instances
(Fig 4). We also showed that SV1 antibodies bind to the surface of eight GAS strains expressing
different M-proteins, but not to the emm-negative GAS JRS145 (Fig 4).
Immuno-safety of SV1
The presence of cross-reactive epitopes within the M-protein has been a major hurdle for all
M-protein vaccine development programs. The ability to demonstrate that immune responses
raised against vaccine candidates do not induce immune responses that cross-react with
human proteins and tissues is an important step before vaccines can proceed to human clinical
trials. Here we first used Western blots using porcine cardiac myosin and skeletal muscle
Fig 4. Anti-SV1 antibody binding to recombinant M-proteins and GAS surface. (A) M-proteins were
electrophoresed in 12% SDS-PAGE gels transferred to nitrocellulose membrane and probed anti-SV1
antisera. The emm-type and emm-cluster assignment are shown at the top of the figure. (B)
Immunofluorescent microscopy demonstrating that anti-SV1 antibodies bind to the surface of multiple GAS
emm-types. The nine strains are (a) JRS145 (emm-negative), (b) 5448, (c) PRS9, (d) PL1, (e) PRS30, (f)
PRS42, (g) PRS15, (h), PRS20 and (i) PRS55. Images are shown as overlays of bright field and fluorescent
images. No fluorescence was observed when PBS sera was used in the same assays (data not shown).
doi:10.1371/journal.pone.0156639.g004
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tropomyosin to show that antibodies from SV1 immunised mice failed to react with these pro-
teins (S1 Fig).
The rat autoimmune valvulitis model is the only animal model available that adequately
mirrors the pathophysiological futures of RHD in humans. To provide a more robust safety
assessment for SV1 as a vaccine candidate we used this model to investigate whether SV1 deliv-
ered in the presence of alum, a human approved adjuvant induced autoimmune inflammatory
responses similar to that observed with RHD. For these experiments rats were immunized with
PBS, recombinant M5 or SV1 in the presence of CFA. A second cohort of rats was immunized
intramuscularly with the same antigens mixed with alum. Mean antibody titers to the immu-
nizing antigen were greater than 105 for SV1 and M5 groups for both antigens (S2 Fig). Signifi-
cant anti-M5 titers were also observed in sera from the SV1 immunized groups. In contrast
titers to SV1 and M5 were less than 100 in the PBS control groups. No cross-reactive antibodies
against cardiac myosin or collagen type 1 were detected in either M5 or SV1 immunized rat
sera (S2 Fig).
T-cell responses to the vaccine were then assessed by measuring [3H] incorporation in
restimulation assays (Fig 5). Splenic T cells fromM5 immunized rats responded strongly to
M5 restimulation irrespective of adjuvant used, weakly to SV1 restimulation, and did not
respond to either cardiac myosin or collagen. Proliferative responses were greater to SV1 that
M5 in the SV1/CFA immunized groups, but there were no differences in the SV1/alum immu-
nized group. No T cell proliferative response to cardiac myosin or collagen was observed in
either of the SV1 immunized groups.
Histological sections from SV1 immunized rats were compared to sections taken from M5-
and PBS-immunized rats to determine whether the candidate SV1 vaccine induced inflamma-
tory changes consistent with valvulitis or myocarditis. Four of the five rats immunized with
M5/CFA had mild or moderate inflammation in the aortic and/or mitral valves. Inflammatory
responses were absent in rats immunized with SV1 or PBS in Freund’s adjuvant (Fig 5). No
inflammatory cell infiltrates were observed in of the groups where mice where immunized with
antigen admixed with alum (S2 Fig).
Overexpression of capsule blocks antibody binding
Capsule is a major GAS virulence factor that, like the M-protein, also inhibits opsonophagocy-
tosis. Total capsule expression levels differ between isolates [35, 36], are up-regulated in differ-
ent host niches [37] and have been reported to block antibody binding to GRAB, another
bacterial protein located on the surface of GAS. Although we saw binding to the surface of
GAS in all immunofluorescent assays, it is possible that overexpression of capsule may also
block SV1 antibody binding. To test this hypothesis we used a FACS based assay to compare
antibody binding to wild-type GAS 5448, a derivative that hyper-expresses capsule [33] and an
acapsular GAS isolate (Fig 6). In contrast to PBS sera, an increase in fluorescence was observed
using anti-SV1 and anti-M1 sera against both the wild-type 5448 strain and ΔhasA acapsular
mutant. However no significant difference in fluorescence was observed between the anti-PBS
and anti-SV1 and anti-M1 sera when the hyper-encapsulated GAS 5448 AP and used in the
same assay (p = 0.157).
Discussion
The greatest mortality associated with GAS infection occurs due to invasive disease and the
autoimmune sequelae RF and RHD [1]. The burden of these diseases is greatest in developing
nations and Indigenous communities within developed nations. Epidemiological studies in
these populations show that multiple emm-types are often circulating, and there is also no
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Fig 5. T cells from SV1 immunized rats do not cross-react with tissue antigens and do not cause
inflammatory changes in cardiac tissue. (A) Data is presented as the change in counts per minute (ΔCPM)
between stimulated and unstimulated groups (A) T-cells responses inSV1/CFA, M5/CFA or PBS/CFA
immunized rats following restimulation with SV1, M5, cardiac myosin or collagen. (B) T cell responses in SV1/
alum, M5/alum or PBS/alum immunized rats following restimulation with SV1, M5, cardiac myosin or
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association between emm-type and disease outcome [21]. Here we have shown that 168 of the
173 M-proteins examined possess a least one of the J14i variants present in SV1. The number
of emm-types examined represents a significant proportion of all known emm-types. The five
M-proteins (emm134, emm174, emm137, emm205 and emm211) possessing variants not rep-
resented in SV1 all had atypical C-repeat regions. Four of these proteins only possessed two
repeat units in their CRR, with a J14i.12:J14i.40 structure. The fifth only had a single CRU har-
boring J14i.12. In the dataset analyzed here J14i.12 was the seventh most common J14i variant,
present in thirteen different emm-types. As we showed that anti-SV1 antibodies bound to
J14i.12, it suggests that these emm-types would all be recognized by SV1 antisera post-vaccina-
tion. The epidemiological and cross-recognition data together suggest that in the absence of
high levels of capsule on the bacterial surface, SV1 antibodies will be able to bind the surface of
the majority, if not all circulating GAS emm-types.
The data reported here may also help to shed light on the coverage offered by other C-termi-
nal GAS vaccines. Our data show that J14i.0 is present in 43% of emm-types. However J14i.0
antibodies were also shown to recognize J14i.1, the most abundant J14i variant, and J14i.2, the
third most common J14i variant. The J8 peptide vaccine candidate includes 12 amino acids
that are identical to 12 of the amino acids present in J14i.0. This candidate and the correspond-
ing J14i sequence have both been shown to induce protective immune responses when conju-
gated to diphtheria toxoid or other molecules and provided the original rationale for targeting
these sequences [16, 17]. Based on this analysis here we would predict J8-DT to also provide
extended M-type coverage. The StreptInCor vaccine candidate developed by Guilherme et al
incorporates a 55 amino acid construct from the C-terminal region from the M5 protein and
includes both human B and T cell epitopes [15, 38]. StreptInCor contains the complete
sequence of the relatively rare J14i.6 sequence, and 12 amino acids at the C-terminus that are
100% identical to multiple J14i variants. As we did not include J14i.6 in our analysis here, we
cannot conclusively demonstrate that this sequence will induce antibodies that recognize mul-
tiple J14i variants. However given the extended length of the sequence, we believe that there is a
strong possibility that it will. Antibodies to StreptInCore have recently been reported to be bac-
tericidal towards five GAS strains [39].
It is imperative that M protein based vaccine candidates do not to induce a deleterious auto-
immune response following immunization. The rat model of valvulitis is a robust model that
has allowed investigators to determine the development of inflammatory, immunopathological
and functional changes in the rat heart that are akin to changes occurring in RHD in human
[26]. Following exposure to M5 it has been shown that rat heart tissue including heart valves
and the myocardium are infiltrated by inflammatory cells that include both macrophages and
lymphocytes [25]. Here we tested SV1, when delivered with a human approved adjuvant, for
its potential to cause autoimmune inflammatory changes that can be detected using this model.
Our observations unequivocally demonstrated that SV1 does not cause any cardiac abnormali-
ties such as those observed following M5 immunization. Therefore we conclude that SV1 is a
safe vaccine candidate that does not have the capacity to induce an autoimmune response.
Finally our results also suggest that increased capsule production may influence the capacity
of anti-SV1 antibodies to access antibody binding sites in the C-repeat region, a finding which
may be also relevant to all GAS vaccine candidates targeting this and other surface antigens
collagen. (C) Representative histology sections of Lewis rat cardiac tissues (x100 magnification) following
immunization with recombinant M5-protein, SV1 or PBS with Freund’s adjuvant. Areas of inflammation are
indicated with a black arrow. A higher magnification image (x400) of an inflamed mitral valve from a rat
immunized with M5 is shown. Mice that received PBS only or SV1 as antigen had no evidence of
inflammatory changes in cardiac tissue.
doi:10.1371/journal.pone.0156639.g005
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[40]. Historically, highly encapsulated strains of GAS are generally considered to be more viru-
lent than isolates with expression lesser capsule, and are associated with rheumatic heart dis-
ease and invasive disease [36, 41]. The role that deployment of a GAS vaccine will play in the
epidemiology of GAS is currently unknown. However as strains that expressing high levels of
capsule are already circulating, the partial or complete blocking of antibody binding to these
isolate may give them increased fitness when compared to strains expressing lesser amounts of
capsule [35, 36]. Overcoming these potential limitations of CRR-targeting vaccines, and indeed
all vaccine targeting proteins on the bacterial surface [13, 42–44], remains a major challenge of
GAS vaccine development.
Supporting Information
S1 Fig. Anti SV1 antibodies do not cross react with cardiac proteins or tissue. (A)Western
blot of porcine cardiac myosin (lane 1), porcine tropomyosin (lanes 2 and 3) and recombinant
M1 (lane 4). Approximate protein sizes indicated by the molecular weight marker (kDa) are
shown on the left.
(TIFF)
S2 Fig. Immunogenicity of SV1 and M5 in rats. Antibody titres to (A) M5 and (B) SV1, (C)
porcine cardiac myosin and (D) collagen type-1 following immunization of rats with SV1 or
M5 in the presence of CFA or alum. No titres were observed against cardiac myosin or collagen
type-1 in these assays.
(TIF)
S3 Fig. Histological analysis of aortic, tricuspid and mitral valves following immunization
of Lewis Rats with M5, SV1 or PBS admixed with alum.No signs in inflammation are visible
Fig 6. Overexpression of capsule reduces antibody binding to the surface of GAS. Representative
histograms showing the binding of anti-SV1 antibodies to (A) the invasive M1 GAS strain 5448, (B) the
acapsular ΔhasA and (C) the capsule overexpressing 5448 AP. Binding and anti-M1 antibodies to the same
strains is shown in panels D-F respectively. In all images the grey shaded histogram represents binding of
sera frommice immunised with PBS to GAS cells and open black lined histograms represent anti-SV1 or anti-
M1-protein antibody binding to GAS strains.
doi:10.1371/journal.pone.0156639.g006
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in the myocardium (m), valves (v) or blood (b).
(TIF)
S1 Table. Distribution of J14i variants in GAS M-types.
(PDF)
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